OBJECTIVE: To compare daily atropine to weekend atropine as prescribed treatments for moderate amblyopia in children younger than 7 years. DESIGN: Prospective, randomized multicenter clinical trial (30 sites). PARTICIPANTS: One hundred sixty-eight children younger than 7 years with amblyopia in the range of 20/40 to 20/80 associated with strabismus, anisometropia, or both. INTERVENTION: Randomization either to daily atropine or to weekend atropine for 4 months. Partial responders were continued on the randomized treatment until no further improvement was noted. MAIN OUTCOME MEASURE: Visual acuity (VA) in the amblyopic eye after 4 months. RESULTS: The improvement in VA of the amblyopic eye from baseline to 4 months averaged 2.3 lines in each group. The VA of the amblyopic eye at study completion was either (1) at least 20/25 or (2) better than or equal to that of the sound eye in 39 children (47%) in the daily group and 45 children (53%) in the weekend group. The VA of the sound eye at the end of follow-up was reduced by 2 lines in one patient in each group. Stereoacuity outcomes were similar in the 2 groups. CONCLUSIONS:Weekend atropine provides an improvement in VA of a magnitude similar to that of the improvement provided by daily atropine in treating moderate amblyopia in children 3 to 7 years old. This article contains additional online-only material available at http://www.ophsource.com/periodicals/ophtha.
RCT Entities:
OBJECTIVE: To compare daily atropine to weekend atropine as prescribed treatments for moderate amblyopia in children younger than 7 years. DESIGN: Prospective, randomized multicenter clinical trial (30 sites). PARTICIPANTS: One hundred sixty-eight children younger than 7 years with amblyopia in the range of 20/40 to 20/80 associated with strabismus, anisometropia, or both. INTERVENTION: Randomization either to daily atropine or to weekend atropine for 4 months. Partial responders were continued on the randomized treatment until no further improvement was noted. MAIN OUTCOME MEASURE: Visual acuity (VA) in the amblyopic eye after 4 months. RESULTS: The improvement in VA of the amblyopic eye from baseline to 4 months averaged 2.3 lines in each group. The VA of the amblyopic eye at study completion was either (1) at least 20/25 or (2) better than or equal to that of the sound eye in 39 children (47%) in the daily group and 45 children (53%) in the weekend group. The VA of the sound eye at the end of follow-up was reduced by 2 lines in one patient in each group. Stereoacuity outcomes were similar in the 2 groups. CONCLUSIONS: Weekend atropine provides an improvement in VA of a magnitude similar to that of the improvement provided by daily atropine in treating moderate amblyopia in children 3 to 7 years old. This article contains additional online-only material available at http://www.ophsource.com/periodicals/ophtha.
Authors: Susan A Cotter; Nicole C Foster; Jonathan M Holmes; B Michele Melia; David K Wallace; Michael X Repka; Susanna M Tamkins; Raymond T Kraker; Roy W Beck; Darren L Hoover; Eric R Crouch; Aaron M Miller; Christie L Morse; Donny W Suh Journal: Ophthalmology Date: 2011-09-29 Impact factor: 12.079
Authors: Eileen E Birch; Simone L Li; Reed M Jost; Sarah E Morale; Angie De La Cruz; David Stager; Lori Dao; David R Stager Journal: J AAPOS Date: 2015-02 Impact factor: 1.220
Authors: David K Wallace; Elizabeth L Lazar; Michael X Repka; Jonathan M Holmes; Raymond T Kraker; Darren L Hoover; Katherine K Weise; Amy L Waters; Melissa L Rice; Robert J Peters Journal: J AAPOS Date: 2015-02 Impact factor: 1.220
Authors: Susan A Cotter; Allison R Edwards; David K Wallace; Roy W Beck; Robert W Arnold; William F Astle; Carmen N Barnhardt; Eileen E Birch; Sean P Donahue; Donald F Everett; Joost Felius; Jonathan M Holmes; Raymond T Kraker; Michele Melia; Michael X Repka; Nicholas A Sala; David I Silbert; Katherine K Weise Journal: Ophthalmology Date: 2006-06 Impact factor: 12.079